GLUE
Monte Rosa Therapeutics, Inc.
NASDAQ · USHealthcareBiotechnology
$23.48-4.40%
Price as of Jul 20, 2026
GLUE financials
Monte Rosa Therapeutics, Inc. financial statements
Annual and quarterly income statement, balance sheet and cash-flow history. On small screens, start with four periods and expand the table when needed.
| Metric | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|
| Income statement | ||||
| Revenue | $123.7M | $75.6M | $0.00 | $0.00 |
| Cost of revenue | $8.4M | $8.1M | $6.2M | $0.00 |
| Gross profit | $115.3M | $67.5M | -$6.2M | $0.00 |
| Operating expenses | $169.5M | $148.6M | $137.1M | $112.4M |
| Operating income | -$54.2M | -$81.1M | -$143.3M | -$112.4M |
| Net income | -$38.6M | -$72.7M | -$135.4M | -$108.5M |
| EBITDA | -$31.4M | -$62.0M | -$128.8M | -$101.0M |
| Basic EPS | $-0.46 | $-0.98 | $-2.63 | $-2.30 |
| Diluted EPS | $-0.46 | $-0.98 | $-2.63 | $-2.30 |
| Balance sheet | ||||
| Cash & equivalents | $129.9M | $224.3M | $128.1M | $54.9M |
| Total assets | $448.7M | $438.7M | $303.8M | $342.4M |
| Total liabilities | $215.6M | $215.8M | $124.5M | $71.0M |
| Stockholders’ equity | $233.1M | $222.9M | $179.3M | $271.4M |
| Total debt | $39.2M | $42.7M | $46.0M | $47.0M |
| Net debt | -$90.7M | -$181.5M | -$82.1M | -$7.9M |
| Cash flow | ||||
| Operating cash flow | -$22.8M | $42.0M | -$43.8M | -$92.5M |
| Capital expenditure | -$4.7M | -$4.0M | -$19.0M | -$12.9M |
| Free cash flow | -$27.5M | $38.0M | -$62.8M | -$105.4M |
| Dividends paid | $0.00 | $0.00 | $0.00 | $0.00 |
| Share repurchases | $0.00 | -$641.0K | $0.00 | $0.00 |